Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology programs including interim safety data evaluating axatilimab (Niktimvo™) in ...
Researchers determined cardiovascular risk factors may be predictive of poorer outcomes in patients with MPNs.
Ruben Mesa, M.D.,Rami S. Komrokji, M.D. Experts Rami Komrokji, MD, and Ruben Mesa, MD, define myeloproliferative neoplasms (MPNs) and explain differences between ...
There are promising drugs for myeloproliferative neoplasms coming down the pipeline. It is an exciting time for the treatment of myeloproliferative neoplasms (MPNs), as new treatments continue to ...
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...
This group of cancers remains a challenge to diagnose, can be rapidly progressive, and requires complex treatment and follow-up care, research suggests. Despite recent advancements in treatments for ...
Researchers identified distinct patterns of epigenetic dysregulation in myeloproliferative neoplasms. Epigenetic changes in myeloproliferative neoplasms (MPNs) have been identified and characterized ...
—In a new study, revascularization reduced major adverse cardiovascular and limb events (MACLE) and amputations, but it increased bleeding and stroke risk, highlighting the need for careful risk ...
—According to a new U.S.-based study, pulmonary hypertension is associated with an increased risk of hematologic progression, adverse cardiovascular events, and all-cause mortality in patients with ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and efficacy of INCA033989, a novel, first in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback